Prime Medicine announces positive Phase 1/2 data for PM359, leadership changes, and strategic pipeline prioritization, focusing on liver diseases. Prime Medicine, Inc. announced initial positive data ...

Prime Medicine announces promising preclinical results for a novel AATD treatment using advanced Prime Editing technology, aiming for clinical trials by mid-2026. Prime Medicine, Inc. announced the ...

-- Initial positive data from Phase 1/2 clinical trial of PM359 in CGD provide clinical proof-of-concept for Prime Editing as a transformative gene editing technology -- -- On-track to file IND and/or ...

Prime Medicine which applies a “search and replace” approach to gene editing, has disclosed plans to go public through an initial public offering (IPO) whose value has been speculated may reach $200 ...

-- Initial positive data from Phase 1/2 clinical trial of PM359 in CGD provide clinical proof-of-concept for Prime Editing as a transformative gene editing technology -- -- On-track to file IND and/or ...

Keith Gottesdiener, MD, former president and CEO of Prime Medicine Prime Medicine is eliminating 25% of its workforce—about 50 jobs—in a restructuring that includes the company pivoting its prime ...